Kyverna Therapeutics, Inc.
NMS: KYTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Kyverna Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KYTX Z-Score →About Kyverna Therapeutics, Inc.
Healthcare
Biotechnology
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
📊 Fundamental Analysis
Kyverna Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -64.7%, which indicates that capital utilization is currently under pressure.
At a current price of $8.95, KYTX currently sits at the 60th percentile of its 52-week range (Range: $1.78 - $13.67).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$541.07M
Trailing P/E
--
Forward P/E
-3.14
Beta (5Y)
2.64
52W High
$13.67
52W Low
$1.78
Avg Volume
719K
Day High
Day Low